A federal advisory committee voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is non-mandatory. The FDA has given no public comment on whether it will adopt the suggestion. The move came after weeks of open hearings. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could reshape how the agency handles a part of the wellness market that is scaling quickly. Industry players are waiting to see if the agency takes up the plan. A spokesperson for the regulator offered no clear schedule for a follow-up. Backers argue the change would open up access to substances some say help. Opponents warn that looser rules could leave gaps in oversight across a quickly growing market. The advisory vote only opens the door to a change, and the final decision rests with the FDA.